Solve FSH invested $3 million to advance Armatus Bio's microRNA-based therapy ARM-201 as a treatment for FSHD, a type of ...

The UCSF professor and frequent YouTube poster has criticized COVID-19 vaccine mandates as well as the accelerated approval ...

Late last year, the therapy developers dosed their first patient following positive preclinical data demonstrating safety and ...

Capricor officials said the company was prepared for the meeting and does not expect it to delay the FDA’s decision on the ...

MEDFORD, Ore.- A fundraiser held at the Children’s Museum of Southern Oregon raises thousands of dollars to help a local boy ...

Duchenne muscular dystrophy (DMD) in India faces challenges in diagnosis, treatment, and support, highlighting the urgent ...

Universities across the country are scrambling to comply with President Donald Trump’s anti-diversity push in an effort to ...

Muscular Dystrophy UK, the leading charity for over 110,000 people in the UK living with one of over 60 muscle-wasting and weakening conditions, spoke with ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2025 and recent business highlights.

Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track ...

Alvin Luk, CEO of HuidaGene, is using his experience in big pharma to lead the small Shanghai and New Jersey-based biotech on ...

Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – ...